Search
Altropane I-123
go.drugbank.com/drugs/DB15144InvestigationalAltropane I-123 is under investigation in clinical trial NCT01950468 (A Cross-Over, Multi-Center Trial to Evaluate the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the
Vilamakitug
go.drugbank.com/drugs/DB18978InvestigationalVilamakitug is under investigation in clinical trial NCT05201352 (Evaluation of Efficacy of Trifluridine/tipiracil Plus an Anti-il-1α True Human Antibody Versus Trifluridine/tipiracil Plus Placebo in Metastatic
Velafermin
go.drugbank.com/drugs/DB06493InvestigationalVelafermin was a novel investigational protein therapeutic, also known as fibroblast growth factor-20 (FGF-20), which promotes both epithelial and mesenchymal cell proliferation in vitro and has demonstrated … activity in multiple animal models.
OP-145
go.drugbank.com/drugs/DB05672ExperimentalOP-145 is a synthetic antimicrobial peptide developed from human cathelicidin LL-37.
Synonyms: -GLUTAMYL-L-ARGINYL-L-ISOLEUCYL-L-LYSYL-L-ARGINYL-L-PHENYLALANYL-L-LEUCYL-L-ARGINYL-L-.ALPHA.-GLUTAMYL-L-LEUCYL-L-VALYL-L-ARGINYL-L-PRO, L-ARGININE, L-ISOLEUCYLGLYCYL-L-LYSYL-L-.ALPHA.-GLUTAMYL-L-PHENYLALANYL-L-LYSYL-L-ARGINYL-L-ISOLEUCYL-L-VALYL-L-.ALPHA.Vercirnon
go.drugbank.com/drugs/DB15250InvestigationalVercirnon is a novel, orally active anti-inflammatory agent that targets a chemokine receptor protein implicated in both Crohn's disease and ulcerative colitis, the two principal forms of IBD. … It is under investigation in clinical trial NCT01611805 (Japanese Phase I of GSK1605786).
International brands: Traficet-ENSR 121463
go.drugbank.com/drugs/DB05455InvestigationalIt is a candidate for control of hyponatremia and in the treatment of syndrome of inappropriate secretion of anti-diuretic hormone (SIADH). … SR 121463 is a nonpeptide aquaretic compound with potent selective antagonism of the vasopressin V2 (V1b) receptor subtype.
Allogenic Donor CD362-enriched Human Umbilical Cord-derived Mesenchymal Stem Cells
go.drugbank.com/drugs/DB15731InvestigationalRegarding the modifications of these UC-MSCs, CD362, also known as syndecan-2, is a surface marker identified on MSCs with enhanced clonogenicity and immunomodulatory properties. … Enrichment of CD362 expression in MSCs is being investigated for its role in immune modulation of injured tissue.
anti-OX40 antibody BMS 986178
go.drugbank.com/drugs/DB15773InvestigationalA macrocyclic peptide (BMS-986189) with activity in binding and functional assays comparable to a PD-L1 antibody.
Folitixorin calcium
go.drugbank.com/drugs/DB05308InvestigationalCoFactor use with 5-FU is being evaluated in clinical trials in first line treatment of metastatic colorectal cancer. … ANX-510 (CoFactor) is a folate-based biomodulator drug being developed to enhance the activity and reduce associated toxicity of the widely used cancer chemotherapy, 5-fluorouracil (5-FU).